[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advancedrecurrent-endometrial-cancer-and-platinum-resistant-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advancedrecurrent-endometrial-cancer-and-platinum-resistant-ovarian-cancer":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100556263",false,"NCT06522828","A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients","Inclusion Criteria:\n\n1. Age:18-75 years old\n2. Advanced endometrial cancer and platinum-resistant ovarian cancer\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=12 weeks.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced\u002Frecurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced\u002Frecurrent endometrial cancer and platinum-resistant ovarian cancer.",[26],"Advanced\u002Frecurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer","RECRUITING","2024-10-17",{"date":30,"type":31},"2024-10-21","ACTUAL",{"date":33,"type":31},"2024-10-10",{"date":35,"type":20},"2026-08",{"name":37,"class":38},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","INDUSTRY",""]